According to the Zhitong Finance App, Jianshi Technology-B (09877) announced interim results for the six months ended June 30, 2026. The group obtained revenue of RMB 64,131 million (same unit), an increase of 377.7%; adjusted net loss of RMB 24.586 million, a year-on-year decrease of 73.2%; the owner of the parent company should have accounted for a loss of 48.69 million yuan, a year-on-year decrease of 71.29%; a loss of 0.11 yuan per share.
During the reporting period, the Group continued to focus on the structural heart disease intervention circuit, firmly implemented the international development strategy, and continued to promote the clinical application and commercialization of core technologies in the global market based on a diversified core product pipeline. Following the beginning of the first year of commercialization in 2025, the Group's commercialization capabilities continued to be realized. Domestic sales of the core product KenValve increased steadily, and a combination of products carried out fee-based clinical implantation in many overseas countries, which led to a significant increase in revenue during the period. As the global registration and commercialization network continues to be rolled out, the Group is expected to continue to maintain a rapid revenue growth trend and lay a solid foundation for long-term sustainable development.
The Group continues to advance the global commercialization development strategy for structural cardiac intervention products. For the six months ended June 30, 2026, the Group achieved revenue of 64.1 million yuan, an increase of 377.7% over the previous year, and a gross margin of 86.5%. Other revenue and revenue were approximately $9.8 million, so the total revenue and revenue generated was about $73.9 million, an increase of 189.8% over the same period last year. The Group's global commercialization process continues to accelerate, the revenue scale expands rapidly, and gradually forms a diversified and sustainable growth engine.